Insomnia treatment
Reading File
Finding Sources
Searching PubMed
"insomnia"[MeSH Terms] AND "therapy"[MeSH Terms]
Searching the Web
insomnia treatment guidelines 2025 CBT-I pharmacotherapy
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from four authoritative textbooks plus current guideline summaries. Here is a complete, well-organized answer.
Insomnia Treatment
Overview
Insomnia is treated using a two-pronged approach: behavioral/psychological therapies (first-line) and pharmacotherapy (adjunctive or when behavioral approaches are unavailable). All major guidelines - American Academy of Sleep Medicine (AASM), European Sleep Society, and others - place Cognitive Behavioral Therapy for Insomnia (CBT-I) above medications as the preferred initial treatment for chronic insomnia.
1. Non-Pharmacological Treatment (First-Line)
Cognitive Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the gold-standard treatment. It is a multicomponent program typically delivered over 6-10 weekly sessions by a trained clinician. It works by addressing maladaptive thoughts and behaviors that perpetuate insomnia. Components include:
- Stimulus control: Use the bed only for sleep/sex; get out of bed if unable to sleep
- Sleep restriction: Limit time in bed to actual sleep time, then gradually extend
- Sleep hygiene education (see table below)
- Cognitive restructuring: Challenge unrealistic beliefs about sleep and consequences of poor sleep
- Relaxation techniques: Progressive muscle relaxation, diaphragmatic breathing
CBT-I shows excellent short- and long-term effectiveness in both younger and older adults. Unlike medications, its benefits are durable and do not carry risks of dependence or tolerance. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 12733
Brief Behavioral Therapy for Insomnia (BBT-I): A 4-session abbreviated form that focuses purely on stimulus control and sleep restriction. It can be delivered by nurses in primary care - useful when access to CBT-I specialists is limited. - Kaplan & Sadock's, p. 12734
Sleep Hygiene (Key Rules)
| Recommendation |
|---|
| Restrict naps to 30 min, in late morning or early afternoon |
| Exercise regularly; spend time outside daily |
| Avoid caffeine, tobacco, and alcohol after midday |
| Avoid electronics (especially blue light) 2 hours before bed |
| Keep the bedroom dark and cool |
| Limit liquids in the evening |
| Maintain a fixed wake time every morning, regardless of sleep duration |
| Use the bedroom only for sleeping |
2. Pharmacological Treatment (Adjunctive or Second-Line)
Medications should be used short-term, and ideally alongside CBT-I rather than instead of it. CBT-I + medication is superior to medication alone; however, adding medication to CBT-I does not produce clinically meaningful improvements over CBT-I alone (AASM 2025 guidance). - Bradley & Daroff's Neurology, p. 2437
Approved Hypnotics by Drug Class
Non-Benzodiazepine GABA-A Agonists ("Z-drugs") - Preferred over BZDs
| Drug | Dose (mg) | Half-life | Indication |
|---|---|---|---|
| Zolpidem (Ambien) | 5-10 | 1.5-2.4 h | Sleep onset |
| Zolpidem ER (Ambien CR) | 6.25-12.5 | ~2.8 h | Onset + maintenance |
| Zaleplon (Sonata) | 5-10 | 1 h | Sleep onset |
| Eszopiclone (Lunesta) | 1-3 | 5-7 h | Onset + maintenance |
Benzodiazepines (short-term only; higher risk profile)
| Drug | Dose (mg) | Half-life |
|---|---|---|
| Temazepam (Restoril) | 7.5-30 | 8-20 h |
| Triazolam (Halcion) | 0.125-0.25 | 2-4 h |
| Flurazepam (Dalmane) | 15-30 | 48-120 h (very long - avoid in elderly) |
| Estazolam | 1-2 | 8-24 h |
Orexin Receptor Antagonists (dual orexin receptor antagonists, DORAs)
- Suvorexant (Belsomra): blocks wake-promoting orexin signaling; useful for sleep maintenance
- Lemborexant (Dayvigo): similar mechanism; generally well tolerated
- DORAs are considered first-line pharmacotherapy by several current guidelines; not yet well-studied in combination with CBT-I (most RCT data come from older hypnotics)
Melatonin Receptor Agonist
- Ramelteon (Rozerem): MT1/MT2 agonist; no abuse potential; useful for sleep-onset insomnia; ideal for patients with substance abuse history
Low-dose Sedating Antidepressants
- Doxepin (Silenor) 3-6 mg: FDA-approved for sleep maintenance insomnia; acts via H1 histamine antagonism at low doses
- Trazodone: off-label, widely used; sedating due to H1 and 5-HT2 antagonism
- Mirtazapine: off-label; useful if comorbid depression/anxiety
Melatonin
- Modest effect: reduces sleep-onset latency and slightly increases total sleep time
- Short half-life; best taken 3-4 hours before desired sleep time for circadian rhythm disturbances
- Children/adolescents: First-line pharmacological agent, especially for those with autism, ADHD, or neurodevelopmental disorders. Prolonged-release melatonin (Slenyto) is EMA/MHRA-approved for autism + insomnia in children. - Maudsley Prescribing Guidelines, p. 645
3. What to Avoid
- Diphenhydramine (Benadryl), doxylamine (OTC sleep aids): minimally effective, impair sleep quality, cause next-day grogginess
- Benzodiazepines in older adults: The American Geriatrics Society Beers Criteria (2019) issues strong recommendations against benzodiazepines, Z-drugs, sedating antidepressants, and first-generation antihistamines for sleep in adults ≥65 - risk of falls, cognitive impairment, and confusion. - Kaplan & Sadock's, p. 12734
- Alcohol: widely misused as a sleep aid; fragments sleep architecture and suppresses REM
- Long-term hypnotic use: increases fall risk, tolerance, dependence, and cognitive effects - especially in elderly
4. Special Populations
| Population | Key Considerations |
|---|---|
| Older adults | CBT-I preferred strongly; avoid most sedative-hypnotics (Beers Criteria); DORAs and low-dose doxepin are relatively safer |
| Pregnancy | Hypnotics are generally inadvisable; non-pharmacological approaches preferred |
| Children/adolescents | Behavioral interventions first; melatonin is first-line medication (especially ASD, ADHD) |
| Alcoholism/substance use | Avoid BZDs and Z-drugs; ramelteon is safe |
| Sleep apnea | Avoid hypnotics; treat the apnea first |
| Advanced renal/hepatic/pulmonary disease | Hypnotics require caution or avoidance |
5. Treatment Algorithm (Summary)
- Identify and treat underlying causes (pain, depression, anxiety, OSA, medications, substance use)
- Start CBT-I for all patients with chronic insomnia (6-10 sessions; or BBT-I in primary care)
- Add short-term pharmacotherapy if CBT-I is insufficient or unavailable:
- Sleep-onset insomnia: Z-drugs (zolpidem, zaleplon), ramelteon
- Sleep-maintenance insomnia: Eszopiclone, zolpidem ER, suvorexant, low-dose doxepin
- Combination therapy (CBT-I + medication) can be considered for patients needing rapid symptom relief, per AASM 2025 guidance - though medication adds only modest benefit over CBT-I alone
- Taper and discontinue medication once CBT-I skills are established
Sources:
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry (insomnia treatment, behavioral and pharmacologic approaches)
- Bradley & Daroff's Neurology in Clinical Practice (approved hypnotics table)
- Adams & Victor's Principles of Neurology, 12th ed. (pharmacotherapy overview, orexin antagonists, melatonin)
- Maudsley Prescribing Guidelines in Psychiatry, 15th ed. (pediatric melatonin)
- AASM 2025 new conditional recommendations on combination CBT-I + pharmacotherapy
This is a shared conversation. Sign in to Orris to start your own chat.